Intra-Cellular Therapies, Inc.
430 E 29th St Ste 900
New York
New York
10016
United States
Website: http://www.intracellulartherapies.com/
Email: info@intracellulartherapies.com
210 articles about Intra-Cellular Therapies, Inc.
-
Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting
4/12/2021
Our research has demonstrated that the phosphodiesterase type 1 (PDE1) enzyme modulates the immune system by reducing macrophage and microglial activity with demonstrated effects in neuroinflammatory conditions, cancer and cardiac diseases. Preclinical findings describing the antitumor effects of PDE1 Inhibitors when administered in conjunction with checkpoint inhibitor immunotherapy are being presented at the American Association for Cancer Research (AACR) virtual annual meeting.
-
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
2/25/2021
Successfully launched CAPLYTA ® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19. CAPLYTA achieved net product revenues of $12.4 million and $22.5 million for fourth quarter and full year 2020, respectively. Fourth quarter CAPLYTA total prescriptions (TRx) increased 77% versus the previous quarter. Pursuing CAPLYTA label expansion including bipolar depression and major depressive disorder:
-
Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
2/24/2021
ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particularly in elderly populations. Phase 1 single ascending dose and multiple ascending dose studies have been completed in healthy volunteers including elderly subjects more than 65 years of age.
-
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
2/22/2021
ITCI submits Supplemental New Drug Applications (sNDAs) for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults. If approved, CAPLYTA has the potential to treat the broadest range of patients with bipolar depression.
-
Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2/19/2021
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the SVB Leerink 10th Annual Global Healthcare Conference
-
Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast
2/17/2021
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, February 25, 2021, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2020
-
CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
1/21/2021
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the publication of results from the CAPLYTA clinical trial (ITI-007-303) in adult patients with schizophrenia.
-
Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
Intra-Cellular Therapies, Inc. announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 9:10 am ET.
-
Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder
12/29/2020
The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials. ITI-333 introduces a unique pharmacology for the treatment of opioid use disorder.
-
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
-
Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology
12/9/2020
Presentations highlight lumateperone ’s broad antidepressant effects in patients with bipolar disorder and in patients with schizophrenia with co-morbid depression NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced two presentations at the 59th Annual Meeting of the American College of
-
Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference
11/30/2020
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference
-
Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
11/9/2020
Intra-Cellular Therapies today announced its financial results for the third quarter ended September 30, 2020, and provided a corporate update.
-
Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast
11/4/2020
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, November 9, 2020, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2020. To a
-
New Ventures Funds Rebrands as Scientia Ventures
10/2/2020
New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.
-
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
10/1/2020
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Dr. Suresh Durgam to the position of Chief Medical Officer.
-
Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
9/15/2020
- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020 at 2:00 pm ET. The live and archived webcast
-
Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference
9/14/2020
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to participate in a fireside chat at the Cantor Virtual Global Healthcare Conference
-
Clinical Catch-Up: September 7-11
9/14/2020
It was a busy week for clinical trial updates. Here’s a look. -
It was a busy week for biopharma, biotech and medical device initial public offerings (IPOs). Here’s a look.